MIR423 (MicroRNA 423)

This study identifies distinct miRNA signatures associated with GBC initiation and progression, offering insights into the molecular pathogenesis of the disease. Furthermore, functional studies of the miRNAs implicated in EMT and EGFR-TKI resistance may be conducted using GBC cell lines to dissect the precise roles of key miRNAs and explore their potential as novel therapeutic targets in GBC.

Interestingly, we also found that medications such as prasterone, tazemetostat, isoxyl, gemcitabine, ponsegromab, scx-2023, and nicotinamide could potentially be used in combination with the identified miRNAs to target ferroptosis in CRC. To further validate the stability and reliability of the predicted protein-ligand interactions, molecular dynamics (MD) simulations and MM-PBSA analyses were performed on selected top-ranking complexes, which confirmed their stable and favorable binding and supported the robustness of our docking results. These findings suggest that targeting these miRNAs and their associated genes, along with using the identified drugs, could be a promising strategy for CRC treatment, leveraging the potential of ferroptosis-inducing therapies.

Circulating miRNA profiling showed upregulation of inflammation-associated miRNAs (miR-21-5p, miR-150-5p, miR-142-3p, miR-363-3p), linked through bioinformatic analysis to immune dysregulation, intestinal cancer, and neurotoxicity. Overall, these results indicate that low-dose exposure to pollutant mixtures can induce subtle but biologically relevant immune and epithelial changes, emphasizing the importance of mixture-based approaches in environmental risk assessment.

PAN3-AS1 exhibits linkage to a cold tumor immune microenvironment (TME) and forecasts durable benefit from immunotherapy. Addressing the PAN3-AS1/miR-423-5p/WFDC13 axis might provide a novel option for improving immunotherapy efficacy in colon cancer.

These structured regions coincide with conserved motifs associated with NF-κB p50 and predicted miRNA binding sites, indicating that PACER function may depend on conformational switching that modulates protein and miRNA accessibility. Together, these findings establish PACER as a regulator of LUAD proliferation and invasion via COX-2 signaling and highlight its potential as a biomarker and therapeutic target in inflammatory cancers.

THBS3-high breast cancer patients exhibited resistance to Dinaciclib, Daporinad, and Rapamycin. THBS3 may promote breast cancer progression through immune regulation, ECM remodeling, and drug resistance mechanisms, suggesting its potential as a therapeutic target. These findings support enhanced breast cancer screening in IBD patients.

The area under the miRNAs curve for differential expression of lymphocytes in Kazakh hypertensive patients, where miR-423-5p, area under the curve (AUC): 0.696 (95% confidence interval (CI): 0.533-0.859); MiR-320a-3p, AUC: 0.764 (95% CI: 0.609-0.919). The expression of miR-92a-3p, miR-423-5p, and miR-320a-3p in T lymphocytes of Kazakh hypertensive patients is downregulated, with good diagnostic reference value (P < .05).

Panel of six miRNAs could be used as reliable marker in differentiating PDAC from chronic pancreatitis with the most impressive difference in miR-196 and miR-423. Key words microRNA " Pancreatic ductal adenocarcinoma " Chronic pancreatitis " Biomarker " CA19-9.

In response to the upstream factor HNRNPA1, hsa-miR-423-5p is selectively loaded into hypoxic exosomes, which then target the downstream protein TAB2 to regulate the autophagy pathway and reduce the sorafenib sensitivity of normoxic hepatocellular carcinoma cells.

Despite these advancements, the clinical integration of novel biomarkers remains limited. This review analyzes the pathophysiological mechanisms underlying CRHM syndrome and explores key biomarkers poised to enhance risk assessment and patient monitoring.

Among the identified candidates, miR-423-5p, AKR1B10, and 3-methylhistidine provide the most robust evidence. Future multicenter, longitudinal studies with standardized protocols and validation are essential.

RT-ICI therapy significantly increases pneumonitis risk in NSCLC, especially in autoimmune comorbidities. A serum exosomal miRNA cluster (miR-148b-3p/301a-3p/423-3p) enables early pneumonitis prediction and prognosis assessment, offering novel targets for prevention and monitoring.